Published in FASEB J on November 17, 2005
Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev (2008) 2.39
NKG2D recognition mediates Toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc Natl Acad Sci U S A (2007) 1.12
Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun (2006) 1.07
Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle (2013) 1.03
Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication. Cell Signal (2015) 0.96
A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol (2013) 0.95
Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology (2013) 0.94
Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev (2009) 0.91
A TRIF-independent branch of TLR3 signaling. J Immunol (2012) 0.86
Stem cell transplantation for muscular dystrophy: the challenge of immune response. Biomed Res Int (2014) 0.83
TLR3 signaling does not affect organ-specific immune responses to factor IX in AAV gene therapy. Blood (2008) 0.81
Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy. PLoS One (2011) 0.80
Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. Int J Hyperthermia (2013) 0.80
The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D. J Biol Chem (2014) 0.78
Chemokine receptor and ligand upregulation in the diaphragm during endotoxemia and Pseudomonas lung infection. Mediators Inflamm (2009) 0.77
The Toll of Vascular Insufficiency: Implications for the Management of Peripheral Arterial Disease. J Immunol Res (2016) 0.76
A critical role for immature muscle precursors in myositis. Nat Rev Rheumatol (2013) 0.76
Major Histocompatibility Complex Class I Chain-Related A (MICA) Molecules: Relevance in Solid Organ Transplantation. Front Immunol (2017) 0.75
The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget (2015) 0.75
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain (2006) 3.16
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 2.50
Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation. Am J Hum Genet (2007) 2.48
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy. Nat Genet (2005) 2.38
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet (2005) 2.33
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet (2009) 2.22
Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood (2010) 2.17
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem (2006) 2.08
The ubiquitin-selective chaperone CDC-48/p97 links myosin assembly to human myopathy. Nat Cell Biol (2007) 2.04
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS. Nat Neurosci (2011) 1.96
A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet (2005) 1.95
Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome. Nat Genet (2009) 1.95
Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol (2005) 1.85
Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit. Am J Hum Genet (2006) 1.84
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 1.83
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res (2005) 1.82
The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat (2013) 1.78
Neurology in sub-Saharan Africa: a challenge for World Federation of Neurology. Neurology (2007) 1.78
5' trans-splicing repair of the PLEC1 gene. J Invest Dermatol (2007) 1.77
Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res (2010) 1.76
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol (2006) 1.74
The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain (2007) 1.73
Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol (2002) 1.71
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res (2006) 1.68
Pathological consequences of VCP mutations on human striated muscle. Brain (2006) 1.68
Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure. J Neurol Neurosurg Psychiatry (2013) 1.64
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood (2012) 1.64
MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res (2003) 1.60
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem (2011) 1.58
Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nat Genet (2003) 1.57
CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol (2008) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. Eur J Immunol (2009) 1.55
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain (2006) 1.54
Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005) 1.54
Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1). Hum Mutat (2009) 1.54
SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet (2009) 1.51
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. J Neurooncol (2008) 1.50
An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet (2008) 1.49
Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol (2003) 1.46
Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord (2007) 1.46
Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs (2014) 1.44
Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci (2005) 1.43
The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol (2008) 1.42
Limb-girdle muscular dystrophies. Curr Opin Neurol (2008) 1.42
A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol (2002) 1.41
Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet (2010) 1.40
Comment on "Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse". Immunol Lett (2009) 1.39
Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol (2011) 1.39
Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet (2011) 1.39
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol (2006) 1.37
Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet (2009) 1.37
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain (2007) 1.35
126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. Neuromuscul Disord (2005) 1.35
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res (2009) 1.34
Risk of developing a mitochondrial DNA deletion disorder. Lancet (2004) 1.34
Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol (2006) 1.34
CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain (2009) 1.33
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum Mol Genet (2011) 1.32
Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol (2012) 1.30
RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med (2014) 1.30
Antimicrobial peptides and proinflammatory cytokines in periprosthetic joint infection. J Bone Joint Surg Am (2013) 1.30
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med (2015) 1.28
Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency. Brain (2010) 1.28
Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. J Immunol (2008) 1.28
New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry (2009) 1.28
The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat (2015) 1.26
Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Ann Neurol (2003) 1.26
Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. Brain (2007) 1.25
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscul Disord (2010) 1.25
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One (2008) 1.24
Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: a study of 680 patients. Hum Mutat (2012) 1.23
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23